Effects of medical and non-medical cannabis use in older adults: protocol for a scoping review.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
28 02 2020
Historique:
entrez: 2 3 2020
pubmed: 3 3 2020
medline: 16 2 2021
Statut: epublish

Résumé

With its legalisation and regulation in Canada in 2018, the proportion of Canadians reporting cannabis use in 2019 increased substantially over the previous year, with half of new users being aged 45+ years. While use in older adults has been low historically, as those born in the 1950s and 1960s continue to age, this demographic will progressively have more liberal attitudes, prior cannabis exposure and higher use rates. However, older adults experience slower metabolism, increased likelihood of polypharmacy, cognitive decline and chronic physical/mental health problems. There is a need to enhance knowledge of the effects of cannabis use in older adults. The following question will be addressed using a scoping review approach: what evidence exists regarding beneficial and harmful effects of medical and non-medical cannabis use in adults >50 years of age? Given that beneficial and harmful effects of cannabis may be mediated by patient-level (eg, age, sex and race) and cannabis-related factors (eg, natural vs synthetic, consumption method), subgroup effects related to these and additional factors will be explored. Methods for scoping reviews outlined by Arksey & O'Malley and the Joanna Briggs Institute will be used. A librarian designed a systematic search of the literature from database inception to June 2019. Using the OVID platform, Ovid MEDLINE will be searched, including Epub Ahead of Print and In-Process and Other Non-Indexed Citations, Embase Classic+Embase, and PsycINFO for reviews, randomised trials, non-randomised trials and observational studies of cannabis use. The Cochrane Library on Wiley will also be searched. Eligibility criteria will be older adult participants, currently using cannabis (medical or non-medical), with studies required to report a cannabis-related health outcome to be eligible. Two reviewers will screen citations and full texts, with support from artificial intelligence. Two reviewers will chart data. Tables/graphics will be used to map evidence and identify evidence gaps. This research will enhance awareness of existing evidence addressing the health effects of medical and non-medical cannabis use in older adults. Findings will be disseminated through a peer-reviewed publication, conference presentations and a stakeholder meeting. DOI 10.17605/OSF.IO/5JTAQ.

Identifiants

pubmed: 32114474
pii: bmjopen-2019-034301
doi: 10.1136/bmjopen-2019-034301
pmc: PMC7050329
doi:

Substances chimiques

Medical Marijuana 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e034301

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: BH has previously received honoraria from Cornerstone Research Group for methodological advice related to the conduct of systematic reviews and meta-analysis.

Références

J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
J Comp Eff Res. 2013 May;2(3):273-82
pubmed: 24236626
Ann Intern Med. 2017 Sep 5;167(5):319-331
pubmed: 28806817
Acad Med. 2017 Feb;92(2):161-166
pubmed: 27782918
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Ann Pharmacother. 2009 Jul;43(7):1347-53
pubmed: 19531696
Health Rep. 2014 Jun;25(6):3-9
pubmed: 24941315
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234
pubmed: 29400010
Ageing Res Rev. 2014 Mar;14:56-64
pubmed: 24509411
Curr Atheroscler Rep. 2017 Jun;19(6):26
pubmed: 28432636
Drug Alcohol Depend. 2018 Jun 1;187:186-194
pubmed: 29679913
Front Pharmacol. 2017 Jun 28;8:422
pubmed: 28701957
J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):45-8
pubmed: 9000780
Syst Rev. 2019 Jul 11;8(1):163
pubmed: 31296265
Addict Behav. 2004 Aug;29(6):1213-9
pubmed: 15236825
Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312
pubmed: 29073741
Psychopharmacology (Berl). 2006 Nov;188(4):425-44
pubmed: 17019571
Curr Opin Psychol. 2019 Dec;30:98-102
pubmed: 31071592
Clin Cardiol. 2002 Mar;25(3):133-4
pubmed: 11890373
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
Res Synth Methods. 2014 Mar;5(1):31-49
pubmed: 26054024
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Syst Rev. 2019 Dec 10;8(1):320
pubmed: 31823819
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Implement Sci. 2010 Sep 20;5:69
pubmed: 20854677
Pain Physician. 2017 Sep;20(6):E755-E796
pubmed: 28934780
J Gen Intern Med. 1999 Apr;14(4):249-54
pubmed: 10203638
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
Int Psychogeriatr. 2011 Jun;23(5):732-41
pubmed: 21108863
AIDS. 2002 Mar 8;16(4):543-50
pubmed: 11872997
Clin Pharmacol Ther. 2017 Feb;101(2):220-229
pubmed: 27861784
Prev Chronic Dis. 2013 Apr 25;10:E65
pubmed: 23618545
Int J Health Policy Manag. 2016 May 25;5(8):453-456
pubmed: 27694657
Drug Alcohol Depend. 2016 Dec 01;169:56-63
pubmed: 27776245
Health Rep. 2018 Jul 18;29(7):3-13
pubmed: 30020531

Auteurs

Dianna Wolfe (D)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Kimberly Corace (K)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada.
The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada.

Danielle Rice (D)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Psychology, McGill University, Montreal, Quebec, Canada.

Andra Smith (A)

Brain and Mind Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

Salmaan Kanji (S)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

David Conn (D)

Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

Melanie Willows (M)

Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada.
Substance Use and Concurrent Disorders Program, The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada.
Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Gary E Garber (GE)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Infection Prevention and Control, Public Health Ontario, Toronto, Ontario, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

John Puxty (J)

Faculty of Medicine, Queen's University, Kingston, Ontario, Canada.

Esther Moghadam (E)

Health Promotion, Ottawa Public Health, Ottawa, Ontario, Canada.

Becky Skidmore (B)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Chantelle Garritty (C)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Kednapa Thavorn (K)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

David Moher (D)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Brian Hutton (B)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada bhutton@ohri.ca.
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH